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Purpose
The efficacy and safety profile of raltegravir in the clini-
cal setting were evaluated retrospectively in HIV Portu-
guese pts treated with raltegravir since the
implementation of Early Access and Compassionate Use
Program.
Methods
Pts from 11 Hospitals were enrolled between Mar07-
Dec08.Three different subgroups of pts were analyzed
(Group1-Pts multi-experienced HIV-1 at virologic fail-
ure, Group2-Pts virologically suppressed who needed to
change ARV due to toxicity, including T20 replacement
and Group3-HIV2 infected pts with failing therapy).
OBT was selected based on previous resistance test and
prior treatment history. Demographics, co-infections,
no. of previous ARV regimens, OBT, adverse reactions
and discontinuations were analysed. Immunologic and
virological responses were evaluated at baseline, weeks
24 and 48. The primary efficacy endpoint was the pro-
portion of pts with RNA<50 cop/mL and change in
TCD4 at weeks 24 and 48. Statistical analysis was per-
formed by SPSS®v18.0.
Results
A total of 151 pts were eligible for the analysis (107 in
Group1, 24 in Group2 and 20 in Group3), 76% were
male with a mean age of 47 years, median TCD4 count
of 180.0 cells and RNA of 4.3 log10cop/mL. Fifty-one
(34%) pts were HCV/HBV co-infected. Median no. of
previous ARV treatments was 5.The proportion of pts
with RNA<50 cop/mL at week24 (week48) was 70%
(69%) in Group1, 100% (100%) in Group2 and 85%
(80%) in Group3.Overall median increase in TCD4
count at week24 was 72.0 cells (83.5 in Group1, 31.5 in
Group2 and 66.0 in Group3) and at week48 was 99.0
cells (124.5 in Group1, 63.0 in Group2 and 50.0 in
Group3).In Group1, 80 pts had PIs in OBT and 76% of
these obtained RNA<50 cop/mL vs. 48% without PIs
(p=0.006), at week48.In Group3, 13 pts had PIs in OBT
and 69% of these obtained RNA<50 cop/mL vs. 100%
without PIs, at week48.Adverse reactions occurred in 11
pts but none led to discontinuation.18 pts discontin-
ued:13 therapeutic failures, 2 lost follow-up and 3 deaths
(not therapy related).In pts with hepatic abnormalities
(AST/ALT) co-infected presented a lower percentage of
G3 than no co-infected (67% vs. 83%)/(75% vs. 83%).
Conclusions
In multiple experienced HIV-infected pts with limited
treatment options, raltegravir+OBT has good efficacy as
demonstrated in obtaining RNA<50 cop/mL and
increasing median TCD4 cell count with a “clean” safety
profile namely in co-infected pts. Contrary to HIV1 pts,
in HIV2 pts the inclusion of PIs in OBT did not reveal
better efficacy.
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